流動性止血材の世界市場 - 2025～2032年

流動性止血材の世界市場は、2024年に8億2,516万米ドルに達し、2032年には15億2,496万米ドルに達すると予測され、予測期間2025年にはCAGR 7.0%で成長すると予測されています。

流動性止血材は、外科手術や外傷治療中の出血をコントロールするために設計された医療製品です。この製品は、物理的なバリアを提供することと、身体の自然な凝固プロセスを積極的に促進することを含む2つの主要なメカニズムの組み合わせによって機能します。第1のメカニズムは、機械的タンポナーデとして機能するゼラチンなどの止血材を含むことです。第二のメカニズムは、トロンビンのような活性成分を含むことで、凝固カスケードを開始する役割を果たします。トロンビンは、フィブリノーゲンをフィブリンに変換することによって血栓の形成を促進し、創傷を効果的に塞ぐ安定した血栓を形成します。

流動性止血材の主な利点の一つは、その汎用性と使いやすさです。これらの製品は通常、液体またはゲル状であるため、手の届きにくい創傷や不規則な形状の創傷であっても、出血部位に直接塗布することが容易です。様々なタイプの創傷に適合するため、創傷が深くても狭くても、また複雑な部位であっても、効果的な出血コントロールを確実にすることができます。

市場力学：

促進要因と阻害要因

外科手術の増加

世界の外科手術件数の増加が、世界の流動性止血材市場を大きく牽引すると予想されます。世界の人口が高齢化し、慢性疾患の有病率が上昇するにつれて、日常的な処置からより複雑な手術に至るまで、外科手術の需要は増加の一途をたどっています。心血管疾患、がん、整形外科的問題などの疾患で外科的介入を必要とする人が増える中、これらの処置中の効果的な出血コントロールの必要性はさらに重要になっています。例えば、2023年の米国国立衛生研究所（National Institute of Health）の発表によると、CABG手術は毎年40万件近く行われており、最も一般的に行われている大手術です。流動性止血材は、患者の安全を確保し、手術成績を向上させるために不可欠な出血を止めるための、迅速で信頼性の高いソリューションを提供するため、この文脈において特に価値があります。

さらに、2023年の世界保健機関（WHO）の報告によると、毎年約119万人が交通事故により死亡しています。交通事故死は5～29歳の小児および若年成人の主な死因であり、予防可能な死因の大部分を出血が占めていることから、外傷治療および外科的介入における流動性止血材の重要な役割が浮き彫りになっています。

流動性止血材の高コスト

流動性止血材、特に特殊な材料やトロンビンのような活性成分を含む進化したバージョンは、ガーゼ、スポンジ、手による圧迫のような出血をコントロールする従来の方法よりも高価になる傾向があります。このようなコストのばらつきは、特に費用対効果が重要視される環境では、ヘルスケア提供者が流動性止血材の採用に消極的になる可能性があります。予算が限られている病院や診療所では、流動性止血材がスピードや効果において優れた性能を発揮したとしても、これらの製品のコストが高いため、より安価な代替品が好まれる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 外科手術の増加
  • 抑制要因
    • 流動性止血材の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品別

• アクティブ止血剤
• 受動止血剤
• 複合止血剤

第7章 素材別

• 豚ゼラチン
• 牛ゼラチン

第8章 用途別

• 一般外科
• 心臓血管外科
• 整形外科
• その他

第9章 エンドユーザー別

• 病院
• クリニック
• 診断検査室
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Aegis Lifesciences
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Baxter
• Teleflex Incorporated
• Becton, Dickinson, and Company
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• 3-D Matrix Medical Technology
• Medcura
• Ferrosan Medical Devices A/S
• Delta Surgical

第13章 付録

The Global flowable hemostats market reached US$ 825.16 million in 2024 and is expected to reach US$ 1524.96 million by 2032, growing at a CAGR of 7.0% during the forecast period 2025-2032.

Flowable hemostats are medical products designed to help control bleeding during surgical procedures or trauma care. They work through a combination of two key mechanisms which include providing a physical barrier and actively promoting the body's natural clotting process. The first mechanism involves a hemostatic material, such as gelatin, which serves as a mechanical tamponade. The second mechanism is the inclusion of an active component, like thrombin, which plays a role in initiating the clotting cascade. Thrombin accelerates the formation of a blood clot by converting fibrinogen into fibrin, creating a stable clot that effectively seals the wound.

One of the key advantages of flowable hemostats is their versatility and ease of use. These products are typically in a liquid or gel-like form, making them easy to apply directly to bleeding sites, even in difficult-to-reach or irregularly shaped wounds. They can conform to various wound types, ensuring effective bleeding control, whether the wound is deep, narrow, or located in a complex area.

Market Dynamics: Drivers & Restraints

Increasing number of surgical procedures

The increasing number of surgical procedures worldwide is expected to significantly drive the global flowable hemostats market. As the global population ages and the prevalence of chronic conditions rises, the demand for surgeries, ranging from routine procedures to more complex operations continues to grow. With more people needing surgical interventions for conditions like cardiovascular disease, cancer, and orthopedic issues, the need for effective bleeding control during these procedures becomes even more critical. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year making it the most commonly performed major surgical procedure. Flowable hemostats are especially valuable in this context because they provide a fast and reliable solution to stop bleeding, which is essential for ensuring patient safety and improving surgical outcomes.

Moreover, according to the World Health Organization report in 2023, approximately 1.19 million people die each year as a result of road traffic crashes. Road traffic injuries are the leading cause of death for children and young adults aged 5-29 years with hemorrhage accounting for a significant portion of preventable deaths, underscoring the critical role of flowable hemostats in trauma care and surgical interventions.

High costs of flowable hemostats

Flowable hemostats, particularly advanced versions that contain specialized materials or active components like thrombin, tend to be more expensive than traditional methods of controlling bleeding, such as gauze, sponges, or manual compression. This cost variation can make healthcare providers reluctant to adopt flowable hemostats, especially in settings where cost-effectiveness is a key consideration. In hospitals or clinics with limited budgets, the high cost of these products can result in a preference for cheaper alternatives, even if flowable hemostats offer superior performance in terms of speed and effectiveness.

Segment Analysis

The global flowable hemostats market is segmented based on product, material, application, end-user, and region.

Product:

Active Hemostats segment is expected to dominate the global Flowable Hemostats share

Active hemostats hold a dominant share of the flowable hemostats market due to their ability to directly boost the body's natural clotting process. These products contain bioactive substances, such as thrombin, that accelerate the formation of a stable blood clot by converting fibrinogen into fibrin. This makes active hemostats much more effective at controlling bleeding compared to passive hemostats, which only work through mechanical methods like pressure or absorption.

The strong market presence of active hemostats is also driven by their versatility and superior performance. While passive hemostats are often used for minor bleeding, active hemostats are favored for more serious bleeding scenarios, especially in complex surgeries like cardiovascular, trauma, or orthopedic procedures. Innovations are being unveiled by the top players with the rising demand for active hemostats. For instance, in April 2023, Baxter International Inc. unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. The innovation also includes the launch of the Floseal + Recothrom flowable hemostat.

As surgical methods become increasingly advanced and minimally invasive, the demand for products that can quickly and effectively address bleeding, even in hard-to-reach areas, continues to rise. This combination of efficiency and versatility ensures that active hemostats continue to dominate the flowable hemostats market.

Geographical Analysis

North America is expected to hold a significant position in the global Flowable Hemostats share

North America is dominant in the global flowable hemostats market due to several key factors that drive demand for advanced bleeding control solutions. The region, particularly the United States, has a highly developed healthcare infrastructure with state-of-the-art hospitals, surgical centers, and research facilities. These medical facilities often perform complex surgeries that require effective bleeding management, making flowable hemostats an essential tool. The strong healthcare system ensures that these products are widely accessible and regularly used across various surgical procedures, from routine operations to high-risk interventions.

The regulatory environment in North America, particularly with regulatory bodies like the FDA, ensures that these products meet stringent quality standards, fostering trust and encouraging their widespread adoption. Furthermore, the region is also experiencing a growing number of surgical procedures, fuelled by an aging population and the rising incidence of chronic diseases like cardiovascular conditions and cancer. For instance, according to the report published by the National Institute of Health in 2023, it is stated that approximately 600,000 hysterectomy procedures are performed annually in the United States (U.S.), making it the most common non-obstetric surgical procedure among women.

As surgeries become more frequent and complex, the demand for effective, easy-to-use hemostatic products continues to rise, further solidifying North America's dominant position in the global flowable hemostats market.

Asia Pacific is at the fastest growing pace in the global flowable hemostats market share

Asia Pacific is currently experiencing the fastest growth in the global flowable hemostats. This is due to the increasing innovation of products that help in early bleeding control. Moreover, the rising prevalence of chronic diseases and an aging population in countries like Japan and China contribute significantly to the increasing number of surgical procedures in the region. With a higher incidence of conditions such as cardiovascular diseases, cancer, and diabetes, the need for complex surgeries and effective blood management solutions is also growing. Flowable hemostats are particularly valuable in these cases due to their ability to provide quick, reliable bleeding control in both traditional and minimally invasive surgeries.

Competitive Landscape

The major global players in the flowable hemostats market include Aegis Lifesciences, Baxter, Teleflex Incorporated, Becton, Dickinson, and Company, Johnson & Johnson Services, Inc., Pfizer Inc., 3-D Matrix Medical Technology, Medcura, Ferrosan Medical Devices A/S and Delta Surgical among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Flowable Hemostats Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Material
• 3.3. Snippet by Application
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing number of surgical procedures
  • 4.1.2. Restraints
    • 4.1.2.1. High costs of flowable hemostats
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Active Hemostats*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Passive Hemostats
• 6.4. Combination Hemostats

7. By Material

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 7.1.2. Market Attractiveness Index, By Material
• 7.2. Porcine Gelatin*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bovine Gelatin

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. General Surgery*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cardiovascular Surgery
• 8.4. Orthopedic Surgery
• 8.5. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Clinics
• 9.4. Diagnostic Laboratories
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Aegis Lifesciences*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Baxter
• 12.3. Teleflex Incorporated
• 12.4. Becton, Dickinson, and Company
• 12.5. Johnson & Johnson Services, Inc.
• 12.6. Pfizer Inc.
• 12.7. 3-D Matrix Medical Technology
• 12.8. Medcura
• 12.9. Ferrosan Medical Devices A/S
• 12.10. Delta Surgical

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us